RATIONALE: Marked reduction in the cortical nicotinic acetylcholine receptors is observed in the brain of patients suffering from Alzheimer's disease (AD). Although cholinesterase inhibitors are used for symptomatic treatment of mild to moderate AD patients, numerous long-term treatment studies indicate that they might stabilize or halt the progression of the disease by restoring the central cholinergic neurotransmission. Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD. OBJECTIVE: To evaluate changes in brain nicotinic binding sites in relation to inhibition level of cholinesterases in cerebrospinal fluid (CSF) and plasma and changes in cognitive performance of the patients in different neuropsychological tests after rivastigmine treatment. MATERIALS AND METHODS: Ten mild AD patients received rivastigmine for 12 months. A dual-tracer PET model with administration of (15)O-water and (S)(-)(11)C-nicotine was used to assess (11)C-nicotine binding sites in the brain at baseline and after 3 and 12 months of the treatment. Cholinesterase activities in CSF and plasma were assessed colorimetrically. RESULTS: The (11)C-nicotine binding sites were significantly increased 12-19% in several cortical brain regions after 3 months compared with baseline, while the increase was not significant after 12 months of the treatment. After 3 months treatment, low enzyme inhibition in CSF and plasma was correlated with higher cortical (11)C-nicotine binding. The (11)C-nicotine binding positively correlated with attentional task at the 12-month follow-up. CONCLUSION: Changes in the (11)C-nicotine binding during rivastigmine treatment might represent remodeling of the cholinergic and related neuronal network.
RATIONALE: Marked reduction in the cortical nicotinic acetylcholine receptors is observed in the brain of patients suffering from Alzheimer's disease (AD). Although cholinesterase inhibitors are used for symptomatic treatment of mild to moderate ADpatients, numerous long-term treatment studies indicate that they might stabilize or halt the progression of the disease by restoring the central cholinergic neurotransmission. Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD. OBJECTIVE: To evaluate changes in brain nicotinic binding sites in relation to inhibition level of cholinesterases in cerebrospinal fluid (CSF) and plasma and changes in cognitive performance of the patients in different neuropsychological tests after rivastigmine treatment. MATERIALS AND METHODS: Ten mild ADpatients received rivastigmine for 12 months. A dual-tracer PET model with administration of (15)O-water and (S)(-)(11)C-nicotine was used to assess (11)C-nicotine binding sites in the brain at baseline and after 3 and 12 months of the treatment. Cholinesterase activities in CSF and plasma were assessed colorimetrically. RESULTS: The (11)C-nicotine binding sites were significantly increased 12-19% in several cortical brain regions after 3 months compared with baseline, while the increase was not significant after 12 months of the treatment. After 3 months treatment, low enzyme inhibition in CSF and plasma was correlated with higher cortical (11)C-nicotine binding. The (11)C-nicotine binding positively correlated with attentional task at the 12-month follow-up. CONCLUSION: Changes in the (11)C-nicotine binding during rivastigmine treatment might represent remodeling of the cholinergic and related neuronal network.
Authors: A Nordberg; H Lundqvist; P Hartvig; J Andersson; M Johansson; E Hellstrŏm-Lindahi; B Långström Journal: Dement Geriatr Cogn Disord Date: 1997 Mar-Apr Impact factor: 2.959
Authors: A Nordberg; P Hartvig; A Lilja; M Viitanen; K Amberla; H Lundqvist; Y Andersson; J Ulin; B Winblad; B Långström Journal: J Neural Transm Park Dis Dement Sect Date: 1990
Authors: Adrian J Mogg; Francis A Jones; Ian A Pullar; Christopher G V Sharples; Susan Wonnacott Journal: Neuropharmacology Date: 2004-11 Impact factor: 5.250
Authors: W Xie; J A Stribley; A Chatonnet; P J Wilder; A Rizzino; R D McComb; P Taylor; S H Hinrichs; O Lockridge Journal: J Pharmacol Exp Ther Date: 2000-06 Impact factor: 4.030
Authors: Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe Journal: Mol Neurobiol Date: 2008-08-09 Impact factor: 5.590
Authors: Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio Journal: Lancet Neurol Date: 2008-02 Impact factor: 44.182
Authors: J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe Journal: Psychopharmacology (Berl) Date: 2008-10-24 Impact factor: 4.530